retatrutide phase 2 trial obesity nejm 2023 triple agonist for Obesity: Weight-Loss Data Retatrutide: A Triple Agonist Shaping

3045 minutes

[DOI] [PubMed] [Google Scholar] 150.Rashvand S., Behrooz M., Samsamikor M., Jacobson K., Hekmatdoost A

These changes often exceed what would be expected from weight loss alone, suggesting direct metabolic effects independent of fat reduction

It is studied in preclinical models to investigate mitochondrial biogenesis enhancement, cellular energy metabolism regulation, neuronal metabolic support, and potential cognitive effects

The rise of GLP-1 adoption is accelerating consumer interest in drinks that offer satiety, balanced blood sugar, and nutrient density with digestive health as a core part of that value proposition, said Ravi Jhala, VP of commercialization at US private label manufacturer, Fedup Foods, which focuses on functional and fermented beverages

Until we have more safety data, tirzepatide remains the more balanced and better-tolerated option